Aspen Neuroscience Inc ASPE

$11.98 -0.25 (-2.04%)

Valuation

Market cap
366,105,000
Revenue TTM
$0
Net income TTM
$-62,056,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
0.00%
Debt to equity
0.00

Trading

Volume
176,980
Avg volume
—
Day's range
$11.84 – $12.80
Shares out
29,079,000
Stochastic %K
32%
Beta
—
Analysts
—
Price target
—

Price

Company profile

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both spor...

Show more

Aspen Neuroscience, Inc. develops autologous induced pluripotent stem cell (iPSC)-derived cell replacement therapies for neurodegenerative diseases. The company's develops ANPD001, an investigational single-dose, autologous dopaminergic neuronal precursor cell (DANPC) therapy for Parkinson's disease. It operates in the United States. The company also advances additional cell replacement candidates targeting both sporadic and genetic forms of Parkinson's disease, as well as other candidates for conditions of the central nervous system (CNS). Aspen Neuroscience, Inc. was formerly known as Aspen Biosciences, Inc. and changed its name to Aspen Neuroscience, Inc. in October 2018. Aspen Neuroscience, Inc. was incorporated in 2018 and is based in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
(858) 263-1222
Website
https://www.aspenneuroscience.com
Address
10835 Road to the Cure, Suite 100, San Diego, United States

Latest news

No headlines yet.